Fiche du document
23 octobre 2018
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.celrep.2018.09.082
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30355485
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2211-1247
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_ADC19C98A2C89
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Citer ce document
S. Saghafinia et al., « Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. », Serveur académique Lausannois, ID : 10.1016/j.celrep.2018.09.082
Métriques
Partage / Export
Résumé
The discovery of cancer-associated alterations has primarily focused on genetic variants. Nonetheless, altered epigenomes contribute to deregulate transcription and promote oncogenic pathways. Here, we designed an algorithmic approach (RESET) to identify aberrant DNA methylation and associated cis-transcriptional changes across >6,000 human tumors. Tumors exhibiting mutations of chromatin remodeling factors and Wnt signaling displayed DNA methylation instability, characterized by numerous hyper- and hypo-methylated loci. Most silenced and enhanced genes coalesced in specific pathways including apoptosis, DNA repair, and cell metabolism. Cancer-germline antigens (CG) were frequently epigenomically enhanced and their expression correlated with response to anti-PD-1, but not anti-CTLA4, in skin melanoma. Finally, we demonstrated the potential of our approach to explore DNA methylation changes in pediatric tumors, which frequently lack genetic drivers and exhibit epigenomic modifications. Our results provide a pan-cancer map of aberrant DNA methylation to inform functional and therapeutic studies.